Lilly in India

India is an integral part of Lilly’s global footprint, contributing significantly to both local impact and global innovation. With an established presence in the country for over three decades, Lilly operates through three business entities in Gurgaon, Bengaluru, and Hyderabad. To better align our efforts and amplify our impact in India, we have implemented the ‘One India’ strategic framework. This approach brings all our entities under one vision, enabling seamless collaboration and reflecting our commitment to growth and innovation in India.

Lilly in Gurgaon is present in India since 1993 and serves as a hub for our commercial operations. We drive the delivery of groundbreaking treatments across key therapeutic areas, including cardiometabolic health, oncology, and immunology. Through our pharmaceutical operations, we serve thousands of patients across the country, addressing critical health needs and improving patient outcomes.

Lilly in Bengaluru stands as a critical global hub accelerating the development and delivery of innovative medicines through cross-functional collaboration and deep scientific expertise and enabling Lilly’s global success. The centre brings together capabilities from Lilly Research Laboratories, Commercial, and Tech@Lilly, enabling operational excellence and innovation at scale.

Lilly in Hyderabad, expected to be operational by mid-2025 is poised to be a transformative force in our global strategy, driving innovation, efficiency, and growth. By leveraging advanced technologies such as automation, AI, software product engineering, and cloud computing, the Hyderabad centre is set to deliver cutting-edge solutions that will enhance our global operations. It will focus on developing advanced deep tech capabilities enabling innovation and operational excellence at scale across Lilly’s global operations.